Hematopoiesis, from haima (Gr., blood) and poiein (Gr., to make), is the production of blood cells, including erythrocytes, leukocytes, and platelets. Also known as hemopoiesis, hematopoiesis first occurs in the blood islands of the yolk sac and then transitions to the liver and spleen duri...
the production ofplatelets(thrombocytes). adj.,adjthrombocytopoiet´ic. Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved. ...
(5) The promegakaryocyte develops into amegakaryocyte. (6) The megakaryocyte is a mature cellular element in the blood responsible for the production ofplatelets (or thrombocytes). The process in which the promegakaryocyte differentiates into a maturemegakaryocyteis called megakaryopoiesis.Thrombopoiet...
Higher AIPN, as marker of active thrombopoiesisis, was associated with worse severity and activity of cGVHD, especially skin and joints/fascia manifestations. Among patients with stable moderate or severe cGVHD, there was no evidence of hypoproduction of platelets. Future studies should further ...
We show that the deletion of BCL-2, on its own or in concert with MCL-1, does not affect platelet production or platelet lifespan. Thrombocytopaenia inBclx-deficient mice was not affected by additional genetic loss or pharmacological inhibition of BCL-2. Thus, BCL-2 is dispensable for ...
Hyperhomocysteinemia (HHcy) is closely associated with thrombotic diseases such as myocardial infarction and stroke. Enhanced platelet activation was observed in animals and humans with HHcy. However, the influence of HHcy on thrombopoiesis remains large
Thrombopoietin (THPO) is the major cytokine that regulates platelet production. This factor controls the proliferation as well as differentiation of megakaryocyte progenitor cells and is essential for the production and maintenance of normal levels of thrombopoiesis [1], [2]. The major sources of THP...
The total number of megakaryocytes in pulmonary tissues is equivalent to that in bone marrow, and the biogenesis of platelets in lung accounts for approximately 50% of total platelet production in whole bodies [23]. As the main deposition organ of the inhaled PMs, [9] lung may thus provide...
We show that the deletion of BCL-2, on its own or in concert with MCL-1, does not affect platelet production or platelet lifespan. Thrombocytopaenia in Bclx-deficient mice was not affected by additional genetic loss or pharmacological inhibition of BCL-2. Thus, BCL-2 is dispensable for ...
Significant efforts are focused on identifying the most suitable cellular and molecular targets to enhance platelet production after bone marrow (BM) transplantation or chemotherapy1. Megakaryocytes (MKs) reside in the BM and maintain the continuous production of circulating platelets in order to prevent...